Connor, Clark & Lunn Investment Management Ltd. Atreca, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $22 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$1.59 - $2.74 $68,311 - $117,718
42,963 Added 79.12%
97,264 $153,000
Q2 2022

Aug 05, 2022
SELL
$1.56 - $3.25 $42,822 - $89,212
-27,450 Reduced 33.58%
54,301 $97,000
Q1 2022

May 12, 2022
BUY
$1.61 - $5.2 $131,619 - $425,105
81,751 New
81,751 $259,000

Others Institutions Holding BCEL

# of Institutions
2
Shares Held
30.6K
Call Options Held
0
Put Options Held
0
View Full List

About Atreca, Inc.

BCEL Quotes by TradingView
  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email